SecBot SecBot
PRESS-RELEASE ·Filed Mar 13, 2026

PPBT

Purple Biotech Ltd.
MIXED
Impact 6/10
Horizonmonths Processed8mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ◆ Mixed

The stock may react positively to the CAPTN-3 platform's preclinical data and extended cash runway, but traders should monitor for partnership developments on discontinued assets and upcoming clinical trial initiations for IM1240. The lack of revenue and continued losses remain key risks.

DirectionMixed
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$4.10
T+0 close · Mar 13, 2026 · via day close
Latest settled
−28.78%
T+60 · $2.92
Vs SPY
−40.40%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 13 $4.10entry
  2. T+1 · 8mo ago −0.24%α −1.27% · $4.09
  3. T+5 · 8mo ago −2.93%α −0.81% · $3.98
  4. T+20 · 7mo ago +0.73%α −2.86% · $4.13
  5. T+60 · 5mo ago −28.78%α −40.40% · $2.92
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Purple Biotech reported a significant net loss of $26.4 million for 2025, driven by a $20.5 million impairment charge related to the discontinuation of CM24 and NT219 programs. However, the company highlighted progress in its CAPTN-3 platform, including preclinical success and a $9.5 million cash position providing runway into 2027. Despite strong R&D advancements, the substantial loss and program discontinuations weigh on near-term fundamentals.

Key Financial Metrics

EPS
$-54.96

Key Facts

  • Reported net loss of $26.4 million for 2025, up from $7.2 million in 2024, primarily due to a $20.5 million impairment charge on CM24 and NT219 programs
  • Cash and cash equivalents totaled $9.5 million as of December 31, 2025, expected to fund operations into 2027
  • Achieved key preclinical milestones for IM1240 and IM1305, including toxicology and manufacturing success, with data showing multi-arm anti-tumor activity
  • R&D expenses decreased to $3.7 million in 2025 from $7.6 million in 2024 due to reduced clinical trial costs, despite increased CMC activities
  • Company will not advance CM24 and NT219 without a strategic partner or additional financing

Financial Impact

Impairment charge of $20.5 million significantly increased net loss; R&D spending cut in half year-over-year excluding non-cash items

net lossintangible assetsR&D expensescash runway

Risk Factors

  • Dependence on future financing or partnerships to advance legacy programs CM24 and NT219
  • High cash burn relative to market cap; any delay in CAPTN-3 development could pressure liquidity
  • Preclinical data may not translate into clinical success; no near-term revenue catalysts

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3255440

US Market Status

Market Closed · Opens in 6h 37m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 13, 2026